These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37190284)

  • 1. Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer.
    Deng G; He J; Huang Q; Li T; Huang Z; Gao S; Xu J; Wang T; Di J
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
    Sun SH; Angell CD; Savardekar H; Sundi D; Abood D; Benner B; DiVincenzo MJ; Duggan M; Choueiry F; Mace T; Trikha P; Lapurga G; Johnson C; Carlson EJ; Chung C; Peterson BR; Lianbo Yu ; Zhao J; Kendra KL; Carson WE
    Cancer Immunol Immunother; 2023 Nov; 72(11):3461-3474. PubMed ID: 37528320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
    Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
    Sagiv-Barfi I; Kohrt HE; Czerwinski DK; Ng PP; Chang BY; Levy R
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E966-72. PubMed ID: 25730880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
    Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
    Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.
    Li C; Fan C; Lu S; Qiu Q; Gao X; Yan X; Wang S; Zhao B; Liu X; Song Y; Deng Y
    Mol Pharm; 2023 Jan; 20(1):438-450. PubMed ID: 36382950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK.
    Li L; Zhao M; Kiernan CH; Castro Eiro MD; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Mueller YM; Katsikis PD
    Front Immunol; 2023; 14():1201415. PubMed ID: 37771591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer.
    Zhu Z; Ling L; Qi L; Chong Y; Xue L
    Onco Targets Ther; 2020; 13():4113-4122. PubMed ID: 32494164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage.
    Guan L; Zhang Z; Gao T; Fu S; Mu W; Liang S; Liu Y; Chu Q; Fang Y; Liu Y; Zhang N
    ACS Nano; 2022 Mar; 16(3):4263-4277. PubMed ID: 35179349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
    Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
    Oncotarget; 2016 Jan; 7(3):2765-79. PubMed ID: 26624983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib in B-cell lymphoma: single fighter might be enough?
    Xue C; Wang X; Zhang L; Qu Q; Zhang Q; Jiang Y
    Cancer Cell Int; 2020; 20():467. PubMed ID: 33005100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
    Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
    J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.